Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer’s Disease
作者:Luiz Antonio Soares Romeiro、Jéssica Larissa da Costa Nunes、Camila de Oliveira Miranda、Gabriella Simões Heyn Roth Cardoso、Andressa Souza de Oliveira、Annachiara Gandini、Tereza Kobrlova、Ondrej Soukup、Michele Rossi、Johanna Senger、Manfred Jung、Silvia Gervasoni、Giulio Vistoli、Sabrina Petralla、Francesca Massenzio、Barbara Monti、Maria Laura Bolognesi
DOI:10.1021/acsmedchemlett.9b00071
日期:2019.4.11
Alzheimer’s disease (AD) represents a global problem, with an estimation of the majority of dementia patients in low- and middle-income countries by 2050. Thus, the development of sustainable drugs has attracted much attention in recent years. In light of this, taking inspiration from the HDAC inhibitor vorinostat (1), we develop the first HDAC inhibitors derived from cashew nut shell liquid (CNSL)
阿尔茨海默氏病(AD)代表了一个全球性问题,据估计,到2050年,低收入和中等收入国家的大多数痴呆患者都将面临这种情况。因此,可持续药物的开发近年来引起了很多关注。鉴于此,我们从HDAC抑制剂vorinostat(1)的启发中,开发了首批源自腰果壳液(CNSL)(一种廉价的农业食品废料)的HDAC抑制剂。CNSL衍生物8和9显示类似于HDAC抑制轮廓1,具有用于一个更有希望的安全一起9相比1。而且,这两种化合物,特别是9能够有效调节神经胶质细胞诱导的炎症并恢复促炎表型。所有这些结果表明,使用廉价的食物垃圾材料可以成功地用于开发可治疗的,可持续的AD候选药物。